Possible Genetic Predictors of Cardiovascular Events After Coronary Bypass Surgery

Purpose: to investigate associations of single nucleotide polymorphisms (SNPs) rs2046934, rs1126643, rs5918, rs6065, rs4244285; rs4986893 with cardiovascular complications (CVC) in patients after CABG. Materials and Methods. We enrolled in this study 130 patients with stable functional class II-IV angina. After CABG 69 patients received ASA (100 mg of enteric form), 61 patients received dual antiplatelet therapy (ASA 100 mg + clopidogrel 75 mg). Mean follow up period was 10.9±5.2 months. The primary composite endpoint included all-cause mortality, myocardial infarction (MI), and ischemic stroke. The control group comprised 185 healthy volunteers. Platelet function was assessed using light transmission aggregometry with ADP (5^M) and arachidonic acid (1 mM). The following single nucleotide polymorphisms (SNPs) were identified by real-time PCR: rs2046934 (H1/H2) on P2RY12 [encoding platelet ADP receptor] (n=100); rs1126643 (C807T, Phe224Phe) on ITGA2 [encoding collagen receptor] (n=87); rs5918 (176 T-kC, Leu33Pro) on ITGB3 [encoding fibrinogen receptor) (n=91); rs6065 (Thr145Met) on GP1BA [encoding platelet receptor for Von Willebrand factor] (n=114); rs4244285 (*2) (n=84), and rs4986893 (*3) (n=83) on CYP2C19 [encoding cytochrome P450 activity]. Results. The prevalence of rs5918, rs6065, rs4244285, rs4986893, rs2046934 did not differ significantly between patients and healthy volunteers. The mutant allele (T ) of ITGA2 was detected more often in healthy volunteers: 67.2% vs 51.7% (р=0.021). Before and after CABG there was no significant difference in platelet aggregation between carries and non-carries of the mutant ITGA2 allele. Number of CVCs registered during follow-up was 12: 3 strokes, 6 MIs, 3 deaths. Patients with composite mutant alleles of ITGB3+СYP2C19*2 or СYP2C19*2+ITGA2, and with the mutant allele (*2) of CYP2C19 met end points more often than patients with other gene combinations (wild type homozygotes, presence of one mutant allele of ITGB3 or ITGA2, the composite of mutant alleles of ITGB3+ITGA2 or ITGB3+ITGA2+ СYP2C19*2) (hazard ratio 4.0, 95% confidence interval 2,19-7.29, р=0.008). Carriers of ITGB3 mutant allele showed higher AA-induced platelet reactivity on the 1st-3rd day after CABG. Amplitude of platelet aggregation in carriers of mutant allele was 27.5% vs 12.7% in wild type (p=0.016). No differences in platelet reactivity among carriers of other mentioned mutant alleles and wild types were observed. Conclusion. Carriage of the combination of mutant alleles ITGB3+СYP2C19*2 or СYP2C19*2+ITGA2 or СYP2C19*2 is possible predictor of CVC in patients after CABG.

коронарное шунтирование, сердечно-сосудистые осложнения, генетические предикторы, coronary artery bypass surgery, cardiovascular events, genetic predictors

1. Geisler T., Schaeffeler E., Gawaz M., Schwab M. Genetic varia tion of platelet function and pharmacology: An update of current knowledge. ^rombosis and Haemostasis 2013;110 (5):876-887 DOI:10.1160/TH13-02-0145.

2. Jones C. I., Bray S., Garner S. F. et al. Bloodomics Consortium A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009;114 (7): 1405-1416. DOI:10.1182/blood-2009-02-202614

3. Затейщиков Д. А., Минушкина Л. О., Чумакова О. С. и др. Кремлевская медицина. Клинический вестник 2014;1:84-91.

4. Quinn M.J., Topol E.J. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2001;2 (4):341-352. DOI: 10.1517/14622416.2.4.341

5. Hoppmann P., Koch W., Laugwitz K. L., Kastrati A. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coronary Artery Disease 2014;25 (8):658-664. DOI: 10.1097/MCA. 0000000000000149

6. Liu H., Wang Y., Zheng J. et al. Platelet glycoprotein gene Ia C807T, HPA-3, and Ib VNTR polymorphisms are associated with increased ischemic stroke risk: Evidence from a comprehensive meta-analysis. International J. Stroke 2017;12 (1):46-70. DOI: 10.1161 / AT VBAHA. 110.218131

7. Гринштейн Ю. И., Савченко А. А., Филоненко И. В., Савченко Е. А. Зилт в сравнении с ацетилсалициловой кислотой у пациентов с атеросклерозом коронарных артерий после аортокоронарного шунтирования. Основные результаты исследования ЗЕВС: эффективность препаратов, механизм резистентности к ацетилсалициловой кислоте, ближайшие и отдаленные клинические результаты. Кардиоваскулярная терапия и профилактика 2009;8 (8):36-43

8. Schneider D.J., Chava S. Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. Coronary Artery Disease 2016;27 (3):185-190. doi: 10.1097/MCA. 0000000000000340.

9. Гринштейн Ю. И., Косинова А. А., Гринштейн И. Ю. и др. Клинико-лабораторные особенности пациентов с ишемической болезнью сердца в периоперационном периоде коронарного шунтирования, резистентных к ацетилсалициловой кислоте: результаты открытого проспективного исследования. Рациональная фармакотерапия в кардиологии 2016;12 (3):264-270

10. Gaikovitch E. A., Cascorbi I., Mrozikiewicz P. M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. European J. Clinical Pharmacology 2003;59 (4):303-312. DOI: 10.1007/s00228-003-0606-2.

11. Комаров А. Л., Панченко Е. П., Донников А. Е. и др. Факторы, определяющие клиническую эффективность клопидогрела и прогноз у больных стабильной формой ишемической болезни сердца. Кардиология 2011;51 (2):8-18

12. Lewandowski K., Swierczynska A., Kwasnikowski P. et al. The prevalence of C807T mutation of glycoprotein Ia gene among young male survivors of myocardial infarction: a relation with coronary angiography results. Kardiologia polska 2005;63 (2):107-discussion114.

13. Zhang Q., Jin Y. Q., Shi D. M. et al. Glycoprotein Ia C807T: Polymorphisms and Their Association with Platelet Function in Patients with the Acute Coronary Syndrome. Cardiology 2015;132 (4):213-220. DOI: 10.1159/000435906.

14. Wu G., Xi Y., Yao L. et al. Genetic polymorphism of ITGA2 C807T can increase the risk ofischemic stroke. InternationalJ Neuroscience 2014;124 (11):841-851. doi: 10.3109/00207454.2013.879718.

15. Dodson P. M., Haynes J., Starczynski J. et al. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. J. Eye Sience 2003;17 (6):772-777. DOI: 10.1038/sj. eye. 6700452.

16. Gerger A., Hofmann G., Langsenlehner U. et al. Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk. International J. Colorectal Disease 2009;24 (2):159-163. DOI: 10.1007/s00384-008-0587-9

17. Motovska Z., Kvasnicka J., Widimsky P. et al. Platelet glycoprotein GP VI 13254C allele is an independent risk factor of premature myocardial infarction. Thrombosis Research 2010;125 (2):E61-E64. DOI: 10.1016/j. thromres. 2009.09.002

18. Ye Z., Liu E. H., Higgins J. P. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66155 cases and 91307 controls. Lancet 2006;367 (9511):651-658. DOI.org/10.1016/S0140-6736 (06) 68263-9

19. Dropinski J., Musial J., Sanak M. et al. Antithrombotic effects of aspirin based on PLA1 /A2 glycoprotein Illa polymorphism in patients with coronary artery disease. Thrombosis Research 2007;119 (3):301-303. DOI: 10.1016/j. thromres. 2006.03.005

20. Lim E., Carballo S., Cornelissen J. et al. Dose-related efficacy of aspirin after coronary surgery in patients with Pl (A2) polymorphism (NCT00262275). Ann 'Rioracic Surgery 2007;83 (1):134-139. DOI: 10.1016/j. athoracsur. 2006.08.002

21. Morawski W., Sanak M., Cisowski M. et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: Role of aspirin and platelet glycoprotein IIIa polymorphism. J. ^oracic Cardiovascular Surgery 2005;130 (3):791-796. DOI: 10.1016/j. jtcvs. 2005.02.041

22. Abderrazek F., Chakroun T., Addad F. et al. THe GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. 'Rirombosis Research 2010;125 (6):E265-E268. DOI: 10.1016/j.thromres. 2010.01.011

23. Kucharska-Newton A. M., Monda K. L., Campbell S. et al. Association of the platelet GPIIb/ IIIa polymorphism with atherosclerotic plaque morphology ^e Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2011;216 ( 1 ) : 151-156. DOI: 10.1016/j. atherosclerosis. 2011.01.038

24. Мирзаев К. Б., Сычев Д. А., Андреев Д. А. Этнические особенности в Российской Федерации полиморфизма гена CYP2C19, ассоциированного с нарушением ответа на клопидогрел. Молекулярная медицина 2014;1:13-21

25. Sibbing D., Stegherr J., Latz W. et al. Cytochrome P4502C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart J. 2009;30 (8):916-922. DOI: 10.1093/eurheartj/ehp041

26. Varenhorst C., James S., Erlinge D. et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart J. 2009;30 (14):1744-1752. DOI: 10.1093/eurheartj/ehp157

27. Liang Z. Y., Han Y. L., Zhang X. L. et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Euro Intervention 2013;9 (3):316-327 doi: 10.4244/EIJV9I3A53

28. Wang Y., Zhao X., Lin J. et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA 2016;316 (1):70-78 DOI: 10.1001/jama. 2016.8662

29. Mega J. L., Close S. L., Wiviott S. D. et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England J. Medicine 2009;360 (4):354-362. DOI: 10.1056/NEJMoa0809171

30. Wallentin L., James S., Storey R. F. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376 (9749):1320-1328. DOI: 10.1016/S0140-6736 (10) 61274-3

31. Holmes M. V., Perel P., Shah T. et al. CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis. J. American Medical Association 2011;306 (24):2704-2714. DOI: 10.1001/jama. 2011.1880.

32. Paré G., Mehta S. R., Yusuf S. et al. Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England J. Medicine 2010;363 (18):1704-1714. DOI: 10.1056/NEJMoa1008410.